Mobile

A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Bio...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-003768-32

A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine versus MenC-CRM197 conjugate vaccine or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Based on the immune response induced one month post vaccination, to select the best of four different formulations of GSK Biologicals’ MenACWY-TT conjugate vaccine when given as one single dose to healthy children aged 12-14 months and 3-5 years.

Critère d'inclusion

  • Primary immunization of healthy children aged 12-14 months and 3-5 years against meningococcal serogroups A, C, W-135 and Y diseases

Liens